Literature DB >> 16466623

Localized and systemic forms of scleroderma in adults and children .

F Atzeni1, A Bardoni, M Cutolo, N Hunzelmann, T Krieg, G Martini, C Montecucco, T M Olski, M E Secchi, G Valentini, F Zulian, P Sarzi-Puttini.   

Abstract

Systemic sclerosis (SSc) presents a great deal of variability in the extent and severity of skin and internal organ involvement. The diagnostic and prognostic significance of autoantibodies in SSc is undisputed and the patient's autoantibody profile represents a fundamental tool for clinicians. Scleroderma is a rare condition in children. Unlike adults, localized scleroderma is more frequent than the systemic sclerosis, nevertheless it represents a disabling condition. In both conditions, no validated outcome measures and proven effective treatment is available to date.Raynaud's phenomenon (RP) is one the most common and significant clinical symptoms of SSc and therefore in patients with RP a capillaroscopic analysis should be carried out as soon as possible. The actual and select advantage of the early nailfold videocapillaroscopic (NVC) analysis is to distinguish between the primary RP and the secondary RP and to allow the early detection of SSc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466623

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  Juvenile Scleroderma: A Referral Center Experience.

Authors:  Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Arch Rheumatol       Date:  2018-01-18       Impact factor: 1.472

Review 2.  Review of orofacial considerations of systemic sclerosis or scleroderma with report of analysis of 3 cases.

Authors:  Arati Panchbhai; Sangita Pawar; Anuradha Barad; Zamzam Kazi
Journal:  Indian J Dent       Date:  2016-09

3.  A cross-sectional electromyography assessment in linear scleroderma patients.

Authors:  Claudia Saad Magalhães; Taciana de Albuquerque Pedrosa Fernandes; Thiago Dias Fernandes; Luis Antonio de Lima Resende
Journal:  Pediatr Rheumatol Online J       Date:  2014-07-12       Impact factor: 3.054

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.